CSPC Innovation Pharmaceutical to Alter Stock Ticker to 'CSPC Innovation'

Stock News06-16

In a recent corporate announcement, Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has declared a change to its stock ticker symbol. The company stated that since 2024, it has leveraged its subsidiary, Jushi Bio, to accelerate its transformation into an innovative biopharmaceutical enterprise. Its strategic focus includes the development of cutting-edge technology platforms such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. The firm is steadily advancing the research, development, and industrialization of its biologic drug pipeline, with products covering multiple therapeutic areas including oncology, metabolic disorders, autoimmune diseases, and infectious diseases. This has resulted in the formation of a complete industrial chain encompassing "R&D—production—commercialization."

To further strengthen its corporate image and brand value, and to better align the stock ticker with the company's core business operations and strategic positioning, the decision has been made to change the ticker from "Xinnuowei" to "CSPC Innovation." The new stock ticker will become effective starting June 17, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189715246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189715246","market":"fut","top_or_hot":-1,"title":"CSPC Innovation Pharmaceutical to Alter Stock Ticker to 'CSPC Innovation'","media":"Stock News","content":"<p>In a recent corporate announcement, <b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (<b>ASX: 300765</b>) has declared a change to its stock ticker symbol. The company stated that since 2024, it has leveraged its subsidiary, Jushi Bio, to accelerate its transformation into an innovative biopharmaceutical enterprise. Its strategic focus includes the development of cutting-edge technology platforms such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. The firm is steadily advancing the research, development, and industrialization of its biologic drug pipeline, with products covering multiple therapeutic areas including oncology, metabolic disorders, autoimmune diseases, and infectious diseases. This has resulted in the formation of a complete industrial chain encompassing \"R&D—production—commercialization.\"<br><br>To further strengthen its corporate image and brand value, and to better align the stock ticker with the company's core business operations and strategic positioning, the decision has been made to change the ticker from \"Xinnuowei\" to \"CSPC Innovation.\" The new stock ticker will become effective starting June 17, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Innovation Pharmaceutical to Alter Stock Ticker to 'CSPC Innovation'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Innovation Pharmaceutical to Alter Stock Ticker to 'CSPC Innovation'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-16 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>In a recent corporate announcement, <b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (<b>ASX: 300765</b>) has declared a change to its stock ticker symbol. The company stated that since 2024, it has leveraged its subsidiary, Jushi Bio, to accelerate its transformation into an innovative biopharmaceutical enterprise. Its strategic focus includes the development of cutting-edge technology platforms such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. The firm is steadily advancing the research, development, and industrialization of its biologic drug pipeline, with products covering multiple therapeutic areas including oncology, metabolic disorders, autoimmune diseases, and infectious diseases. This has resulted in the formation of a complete industrial chain encompassing \"R&D—production—commercialization.\"<br><br>To further strengthen its corporate image and brand value, and to better align the stock ticker with the company's core business operations and strategic positioning, the decision has been made to change the ticker from \"Xinnuowei\" to \"CSPC Innovation.\" The new stock ticker will become effective starting June 17, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1152091168.USD","symbol_name":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","start_time":0,"source_url":"","article_id":"1189715246","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189715246","pubTimestamp":1781601865,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"In a recent corporate announcement, Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has declared a change to its stock ticker symbol. The company stated that since 2024, it has leveraged its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","300765":"石药创新","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","BK1191":"制药","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK0226":"食品制造","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","01093":"石药集团","BK1515":"抗疫概念","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"石药创新制药将股票代码更改为“石药创新”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"300765":1,"01093":1},"content_text":"In a recent corporate announcement, Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has declared a change to its stock ticker symbol. The company stated that since 2024, it has leveraged its subsidiary, Jushi Bio, to accelerate its transformation into an innovative biopharmaceutical enterprise. Its strategic focus includes the development of cutting-edge technology platforms such as antibody drugs, antibody-drug conjugates (ADCs), and mRNA vaccines. The firm is steadily advancing the research, development, and industrialization of its biologic drug pipeline, with products covering multiple therapeutic areas including oncology, metabolic disorders, autoimmune diseases, and infectious diseases. This has resulted in the formation of a complete industrial chain encompassing \"R&D—production—commercialization.\"To further strengthen its corporate image and brand value, and to better align the stock ticker with the company's core business operations and strategic positioning, the decision has been made to change the ticker from \"Xinnuowei\" to \"CSPC Innovation.\" The new stock ticker will become effective starting June 17, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189715246","isCrawlerRequest":true}